These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8769383)

  • 1. Cardiovascular aspects in acromegaly: effects of treatment.
    Lombardi G; Colao A; Ferone D; Marzullo P; Landi ML; Longobardi S; Iervolino E; Cuocolo A; Fazio S; Merola B; Sacca L
    Metabolism; 1996 Aug; 45(8 Suppl 1):57-60. PubMed ID: 8769383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular consequences of early-onset growth hormone excess.
    Colao A; Spinelli L; Cuocolo A; Spiezia S; Pivonello R; di Somma C; Bonaduce D; Salvatore M; Lombardi G
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3097-104. PubMed ID: 12107207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly.
    Colao A; Marzullo P; Ferone D; Spinelli L; Cuocolo A; Bonaduce D; Salvatore M; Boerlin V; Lancranjan I; Lombardi G
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3132-40. PubMed ID: 10999798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly.
    Colao A; Cuocolo A; Marzullo P; Nicolai E; Ferone D; Florimonte L; Salvatore M; Lombardi G
    J Clin Endocrinol Metab; 1999 Jan; 84(1):17-23. PubMed ID: 9920056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance.
    Colao A; Cuocolo A; Marzullo P; Nicolai E; Ferone D; Della Morte AM; Pivonello R; Salvatore M; Lombardi G
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1551-7. PubMed ID: 11297582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of octreotide pretreatment on surgical outcome in acromegaly.
    Colao A; Ferone D; Cappabianca P; del Basso De Caro ML; Marzullo P; Monticelli A; Alfieri A; Merola B; Calì A; de Divitiis E; Lombardi G
    J Clin Endocrinol Metab; 1997 Oct; 82(10):3308-14. PubMed ID: 9329359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of treatment with somatostatin analogues on QT interval duration in acromegalic patients.
    Fatti LM; Scacchi M; Lavezzi E; Pecori Giraldi F; De Martin M; Toja P; Michailidis G; Stramba-Badiale M; Cavagnini F
    Clin Endocrinol (Oxf); 2006 Nov; 65(5):626-30. PubMed ID: 17054464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cardiovascular effects of octreotide treatment in acromegaly: an echocardiographic study.
    Thuesen L; Christensen SE; Weeke J; Orskov H; Henningsen P
    Clin Endocrinol (Oxf); 1989 Jun; 30(6):619-25. PubMed ID: 2591060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Octreotide treatment increases exercise capacity in patients with acromegaly.
    Padayatty SJ; Perrins EJ; Belchetz PE
    Eur J Endocrinol; 1996 May; 134(5):554-9. PubMed ID: 8664974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiopulmonary performance during exercise in acromegaly, and the effects of acute suppression of growth hormone hypersecretion with octreotide.
    Giustina A; Boni E; Romanelli G; Grassi V; Giustina G
    Am J Cardiol; 1995 May; 75(15):1042-7. PubMed ID: 7747686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GH and IGF-I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment.
    Colao A; Terzolo M; Bondanelli M; Galderisi M; Vitale G; Reimondo G; Ambrosio MR; Pivonello R; Lombardi G; Angeli A; degli Uberti EC
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):613-20. PubMed ID: 18410555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac effect of thyrotoxicosis in acromegaly.
    Marzullo P; Cuocolo A; Ferone D; Pivonello R; Salvatore M; Lombardi G; Colao A
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1426-32. PubMed ID: 10770177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Octreotide as primary therapy for acromegaly.
    Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum ghrelin levels in acromegaly: effects of surgical and long-acting octreotide therapy.
    Freda PU; Reyes CM; Conwell IM; Sundeen RE; Wardlaw SL
    J Clin Endocrinol Metab; 2003 May; 88(5):2037-44. PubMed ID: 12727951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Echocardiographic evidence for a direct effect of GH/IGF-I hypersecretion on cardiac mass and function in young acromegalics.
    Minniti G; Jaffrain-Rea ML; Moroni C; Baldelli R; Ferretti E; Cassone R; Gulino A; Tamburrano G
    Clin Endocrinol (Oxf); 1998 Jul; 49(1):101-6. PubMed ID: 9797853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostatic hyperplasia: an unknown feature of acromegaly.
    Colao A; Marzullo P; Ferone D; Spiezia S; Cerbone G; Marinò V; Di Sarno A; Merola B; Lombardi G
    J Clin Endocrinol Metab; 1998 Mar; 83(3):775-9. PubMed ID: 9506725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy.
    Colao A; Baldelli R; Marzullo P; Ferretti E; Ferone D; Gargiulo P; Petretta M; Tamburrano G; Lombardi G; Liuzzi A
    J Clin Endocrinol Metab; 2000 Jan; 85(1):193-9. PubMed ID: 10634386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
    Damjanovic SS; Neskovic AN; Petakov MS; Popovic V; Macut D; Vukojevic P; Joksimovic MM
    Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular complications in acromegaly.
    Vitale G; Pivonello R; Lombardi G; Colao A
    Minerva Endocrinol; 2004 Sep; 29(3):77-88. PubMed ID: 15282442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired cardiac performance is a distinct feature of uncomplicated acromegaly.
    Fazio S; Cittadini A; Cuocolo A; Merola B; Sabatini D; Colao A; Biondi B; Lombardi G; Saccà L
    J Clin Endocrinol Metab; 1994 Aug; 79(2):441-6. PubMed ID: 8045960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.